{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:23:31Z","timestamp":1787851411798,"version":"build-2784847793"},"reference-count":40,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.esmoop.2026.108325","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T21:15:30Z","timestamp":1784668530000},"page":"108325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Eribulin versus taxane as first-line chemotherapy combined with dual HER2 blockade in patients with HER2-positive locally advanced or metastatic breast cancer: final survival outcomes of the JBCRG-M06\/EMERALD study"],"prefix":"10.1016","volume":"11","author":[{"given":"S.","family":"Saji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6260-6943","authenticated-orcid":false,"given":"J.","family":"Tsurutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Sagara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9393-9655","authenticated-orcid":false,"given":"H.","family":"Shigematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8417-5291","authenticated-orcid":false,"given":"T.","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6641-9598","authenticated-orcid":false,"given":"M.","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7623-7715","authenticated-orcid":false,"given":"K.","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tsuneizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Yanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Osaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1822-2720","authenticated-orcid":false,"given":"K.","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"31","key":"10.1016\/j.esmoop.2026.108325_bib1","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108325_bib2","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.3390\/cancers15061738","article-title":"HER2-positive metastatic breast cancer: available treatments and current developments","volume":"15","author":"Essadi","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108325_bib3","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s11864-023-01137-5","article-title":"Anti-HER2 drugs for the treatment of advanced HER2 positive breast cancer","volume":"24","author":"Stanowicka-Grada","year":"2023","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108325_bib4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108325_bib5","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108325_bib6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","volume":"14","author":"Swain","year":"2013","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108325_bib8","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2026.108325_bib9","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1200\/JCO.22.00519","article-title":"Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update","volume":"40","author":"Giordano","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108325_bib10","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1007\/s10072-021-05576-6","article-title":"Chemotherapy and peripheral neuropathy","volume":"42","author":"Li","year":"2021","journal-title":"Neurol Sci"},{"issue":"9769","key":"10.1016\/j.esmoop.2026.108325_bib11","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108325_bib12","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108325_bib13","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10549-014-3144-y","article-title":"Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies","volume":"148","author":"Twelves","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2026.108325_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103375","article-title":"Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer: a systematic review and meta-analysis","volume":"163","author":"Tanni","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108325_bib15","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1002\/ijc.32402","article-title":"Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program","volume":"145","author":"Jacot","year":"2019","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108325_bib16","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10549-020-05867-0","article-title":"Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine","volume":"184","author":"Kazmi","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108325_bib17","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1111\/ajco.12863","article-title":"A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimens","volume":"14","author":"Kikuchi","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108325_bib18","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO-24-01888","article-title":"Trastuzumab-pertuzumab plus eribulin or taxane as first-line chemotherapy for human epidermal growth factor 2-positive locally advanced\/metastatic breast cancer: the randomized noninferiority phase III EMERALD trial","volume":"43","author":"Yamashita","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108325_bib19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/bs.ircmb.2024.08.006","article-title":"Identification of circulating tumor DNA as a biomarker for diagnosis and response to therapies in cancer patients","volume":"391","author":"Hsieh","year":"2025","journal-title":"Int Rev Cell Mol Biol"},{"key":"10.1016\/j.esmoop.2026.108325_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2025.120513","article-title":"Advances in prognostic and predictive biomarkers for breast cancer: integrating multigene assays, hormone receptors, and emerging circulating biomarkers","volume":"578","author":"Mondal","year":"2026","journal-title":"Clin Chim Acta"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108325_bib21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","article-title":"Liquid biopsy enters the clinic\u2013implementation issues and future challenges","volume":"18","author":"Ignatiadis","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108325_bib22","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/cas.16148","article-title":"HER2 mutation as an emerging target in advanced breast cancer","volume":"115","author":"Bon","year":"2024","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108325_bib23","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1186\/s12885-022-10078-5","article-title":"PIK3CA mutation status, progression and survival in advanced HR+\/HER2\u2212 breast cancer: a meta-analysis of published clinical trials","volume":"22","author":"Fillbrunn","year":"2022","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108325_bib24","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.3390\/ijms24043590","article-title":"HER2 amplification level predicts pathological complete response in the neoadjuvant setting of HER2-overexpressing breast cancer: a meta-analysis and systematic review","volume":"24","author":"Gonullu","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108325_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188847","article-title":"Predictive and prognostic value of PIK3CA mutations in HER2-positive breast cancer treated with tyrosine kinase inhibitors: a systematic review and meta-analysis","volume":"1878","author":"Shi","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.esmoop.2026.108325_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2025.100312","article-title":"Liquid biopsy in breast cancer: redefining precision medicine","volume":"9","author":"Schiavone","year":"2025","journal-title":"J Liq Biopsy"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108325_bib27","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/bcr3605","article-title":"PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data","volume":"16","author":"Zardavas","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"33","key":"10.1016\/j.esmoop.2026.108325_bib28","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.2013.54.5384","article-title":"Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer","volume":"32","author":"Baselga","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108325_bib29","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1186\/s13063-020-04341-y","volume":"21","author":"Yamashita","year":"2020","journal-title":"Trials"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108325_bib30","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3390\/genes15060792","article-title":"Significance of multi-cancer genome profiling testing for breast cancer: a retrospective analysis of 3326 cases from Japan\u2019s national database","volume":"15","author":"Kawabata","year":"2024","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.esmoop.2026.108325_bib31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ctrv.2016.03.004","article-title":"New insights on PI3K\/AKT pathway alterations and clinical outcomes in breast cancer","volume":"45","author":"Yang","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"23","key":"10.1016\/j.esmoop.2026.108325_bib32","doi-asserted-by":"crossref","first-page":"10992","DOI":"10.1158\/0008-5472.CAN-05-2612","article-title":"Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells","volume":"65","author":"Isakoff","year":"2005","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108325_bib33","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108325_bib34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13058-017-0806-9","article-title":"Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer","volume":"19","author":"Bianchini","year":"2017","journal-title":"Breast Cancer Res"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108325_bib35","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3690","article-title":"Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study","volume":"16","author":"Schneeweiss","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108325_bib36","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/978-3-031-70875-6_24","article-title":"HER2-positive breast cancer treatment and resistance","volume":"1464","author":"Veeraraghavan","year":"2025","journal-title":"Adv Exp Med Biol"},{"issue":"46","key":"10.1016\/j.esmoop.2026.108325_bib37","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023053","article-title":"Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer","volume":"99","author":"Choi","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108325_bib38","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13058-023-01746-w","article-title":"HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results","volume":"25","author":"Seo","year":"2023","journal-title":"Breast Cancer Res"},{"issue":"14","key":"10.1016\/j.esmoop.2026.108325_bib39","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1158\/1078-0432.CCR-16-2373","article-title":"Pathological complete response to neoadjuvant trastuzumab is dependent on HER2\/CEP17 ratio in HER2-amplified early breast cancer","volume":"23","author":"Singer","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.esmoop.2026.108325_bib40","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1158\/1078-0432.CCR-22-3785","article-title":"Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer","volume":"29","author":"Hensing","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108325_bib41","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJMoa2508668","article-title":"Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N Engl J Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:34:45Z","timestamp":1787848485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926022672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2059702926022672"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108325","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eribulin versus taxane as first-line chemotherapy combined with dual HER2 blockade in patients with HER2-positive locally advanced or metastatic breast cancer: final survival outcomes of the JBCRG-M06\/EMERALD study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108325","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108325"}}